Recruitment

Recruitment Status
Not yet recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Coronary Artery Bypass Grafting
  • Hypotension
Type
Interventional
Phase
Not Applicable
Design
Allocation: Non-RandomizedIntervention Model: Crossover AssignmentIntervention Model Description: Pragmatic, prospective, single-center, unit-based cluster crossover, open-label registryMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Personalized Arm: The target MAP will be defined as +10% of the resting MAP. Resting MAP will be defined in priority order using one of the following MAP measurements: Pre-operative anesthesia or surgical consultation; Other physician outpatient consultation (e.g. cardiology, family physician, inter...

Personalized Arm: The target MAP will be defined as +10% of the resting MAP. Resting MAP will be defined in priority order using one of the following MAP measurements: Pre-operative anesthesia or surgical consultation; Other physician outpatient consultation (e.g. cardiology, family physician, internist) within 30 days of surgery; Inpatient measurement the night before surgery; Pre-anesthetic MAP The lower and upper safety limits of personalized MAP targets will be 50mmHg and <90mmHg, respectively. Protocolized Arm: The target MAP will be defined as 65 +/- 5mmHg. Pharmacologic and fluid treatment decisions will be at the discretion of the most responsible physician. In both study arms, the blood pressure control period will extend from anesthetic induction until 12 hours after admission to the CSICU. As an additional safety metric, the anesthesiologist will be encouraged to utilize clinically-driven cerebral saturation monitoring to identify potential hypoperfusion. In cases with low bilateral saturations where the anesthesiologist feels low MAP may be the putative mechanism, the investigators will request that MAPs be raised in 5mmHg increments. Following completion of the study protocol, the MAP and/or systolic blood pressure targets will be at the discretion of the most responsible physician.

Tracking Information

NCT #
NCT04197700
Collaborators
Canadian VIGOUR Centre
Investigators
Principal Investigator: Sean van Diepen, MD University of Alberta